Physician profile
Ginger Conn
NPI 1730667759
$1,895.54
in general payments reported to CMS, 2019-2025
23 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $442 · 2022: $117 · 2023: $385 · 2024: $537 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,336.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $509.74 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $286.99 | 2022-2025 | Rexulti, Abilify Maintena |
| Indivior INC. | $170.57 | 2024-2025 | Sublocade |
| Lilly USA, LLC | $129.00 | 2021-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $91.44 | 2021 | |
| Neurelis, INC. | $87.91 | 2021 | |
| Vanda Pharmaceuticals INC. | $86.17 | 2024-2025 | Fanapt |
| Glaxosmithkline, LLC. | $83.16 | 2021-2025 | Trelegy Ellipta |
| Intuitive Surgical, INC. | $72.62 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $60.94 | 2023 | Austedo |
| Braeburn INC. | $44.74 | 2024-2025 | Brixadi |
| Axsome Therapeutics, INC. | $43.00 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $38.91 | 2021 | |
| Shield Therapeutics INC | $37.06 | 2023 | Accrufer |
| Novartis Pharmaceuticals Corporation | $26.04 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.98 | 2024 | Caplyta |
| Abbott Laboratories | $19.01 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2024 | |
| Neurocrine Biosciences, INC. | $14.68 | 2022 | |
| Alkermes, INC. | $14.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.04 | 2021 | |
| Avion Pharmaceuticals | $13.18 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Conn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.